| SARS-CoV-2 IgG-IgM positive | SARS-CoV-2 IgG-IgM negative | |
| Samples analyzed | 83 (5%) | 1503 (95%) |
| Median age (IQR*) | 43 (32 - 55) | 46 (35.5 - 56) |
| Sex | ||
| Male | 36 (43%) | 722 (48%) |
| Female | 47 (57%) | 781 (52%) |
| Age, years |
|
|
| 4 - 20 | 5 (6%) | NA |
| 21 - 64 | 72 (87%) | NA |
| ≥65 | 6 (7%) | NA |
| Presenting symptoms | 38 (45%) | 95 (6.3%) |
| Fever | 21 (25%) | 38 (2.5%) |
| Cough | 4 (4.8%) | 16 (1%) |
| Bronchitis | 1 (1.2%) | ND |
| Fever, diarrhea | 1 (1.2%) | 23 (1.5%) |
| Fever, Cough, Olfactory and Gustatory dysfunctions | 2 (2.4%) | ND |
| Olfactory and Gustatory dysfunctions | 3 (3.6%) | 7 (0.4%) |
| Olfactory and Gustatory dysfunctions, Fever | 2 (2.4%) | 5 (0.5%) |
| Olfactory dysfunction | 4 (4.8%) | 2 (0.1%) |
| Gastrointestinal dysfunction | ND | 4 (3%) |
| Laboratory results |
|
|
| IgG-positive | 37 (45%) | ND |
| IgM-positive | 6 (7%) | ND |
| IgG & IgM-positive | 40 (48%) | ND |